ArticleComputational and structural biotechnology journal2025
ASOG: AntiSense Oligonucleotide Generator.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Safety and toxicity assessment of antisense oligonucleotides in brain-relevant human cellular models.Molecular therapy. Nucleic acids · 2026Review
- Survivin-Targeting Antisense Oligonucleotides in Cancer Therapy.Molecules (Basel, Switzerland) · 2026Review
- ClinASO: An open-source platform for rapid drug discovery of gapmer antisense oligonucleotides.Molecular therapy. Nucleic acids · 2026Article
- BlendSplice: A Frequency-Blended Generative Framework forComputational and structural biotechnology journal · 2026Article
- Generative Chemistry Platform for Small Molecules Targeting RNA: A Case Study for Chemical Optimization.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisense oligonucleotides (ASOs) are used in both fundamental research and clinical applications to modulate gene expression by targeting the RNA transcript of specific genes. Historically, ASOs were designed manually, a time-consuming process that limited exhaustive searches through the ASO space. More recently, resources have been developed based on traditional or deep learning approaches to facilitate ASO design, each with their specific use cases and limitations. In this context, we propose an original and generalistic pipeline for ASO design, based on explicit criteria, original algorithms, and third-party software, encapsulated in a web application we named AntiSense Oligonucleotide Generator (ASOG). The ASOG pipeline requires only a target gene sequence as input, and it proceeds with ASO generation, predicts the structural properties of target subsequences, predicts splice site masking, detects off-target effects, and computes thermodynamic hybridization parameters, taking into account some of the most common RNA modifications. ASOG is designed to enable users to quickly navigate the ASO space, assisting them in making informed decisions. The ASOG webserver is available at asog.iecb.u-bordeaux.fr.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.